Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions

Abstract

The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilized by sequence modifications and optimized for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilization and translational efficiency of modified mRNA of the invention.

Claims

1. A cell-free mRNA pharmaceutical composition comprising at least one modified mRNA and a pharmaceutically compatible carrier, wherein the modified mRNA encodes at least one human tumour-specific antigenic polypeptide capable of stimulating an immune response in a patient against the human tumour-specific antigenic polypeptide wherein said modified mRNA encoding the human tumour-specific antigenic polypeptide has been stabilized by increasing its Guanosine/Cytosine (G/C) content by at least 7 percentage points relative to that of the wild type mRNA encoding the tumour-specific antigenic polypeptide.

2. The mRNA pharmaceutical composition according to claim 1, wherein the modified mRNA encoding the human tumour-specific antigenic polypeptide comprises a sequence wherein at least one codon of a wild type sequence recognized by a rare cellular tRNA is replaced with a codon recognized by an abundant cellular tRNA, and wherein said rare cellular tRNA and said abundant cellular tRNA recognize the same amino acid.

3. The mRNA pharmaceutical composition according to claim 2, wherein the modified mRNA encoding the human tumour-specific antigenic polypeptide comprises a maximum G/C content and a maximum number of codons recognized by abundant tRNAs.

4. The mRNA pharmaceutical composition of claim 1, wherein the modified mRNA further encodes a secretory leader.

5. The mRNA pharmaceutical composition of claim 1, which is formulated for injection.

6. The mRNA pharmaceutical composition according to claim 1, wherein the G/C content of the modified mRNA is increased by at least 15 percentage points relative to that of the wild type mRNA.

7. The mRNA pharmaceutical composition of claim 1, wherein the tumour is a malignant melanoma, colon carcinoma, lymphoma, sarcoma, small-cell lung carcinoma, or blastoma.

8. The mRNA pharmaceutical composition of claim 1, wherein the tumour is a small-cell lung carcinoma.

9. The mRNA pharmaceutical composition of claim 1, wherein the mRNA pharmaceutical composition comprises more than one modified mRNA, wherein each modified mRNA encodes a different human tumour-specific antigenic polypeptide resulting in the stimulation of an immune response in the patient against the human tumour antigenic polypeptide.

10. The mRNA pharmaceutical composition according to claim 1, wherein the at least one modified human mRNA is dissolved in the aqueous carrier material.

11. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material is water for injection (WFI).

12. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material is a buffered solution.

13. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material is a solution buffered with phosphate.

14. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material is a solution buffered with citrate.

15. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material is a solution buffered with acetate.

16. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material is a salt solution.

17. The mRNA pharmaceutical composition of claim 16, wherein the salt solution is a sodium chloride or potassium chloride solution.

18. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material is a solution comprising a component selected from the group consisting of human serum albumin, a polycationic protein, polysorbate 80, a sugar and an amino acid.

19. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material is a phosphate buffered saline solution of polycationic protein.

20. The mRNA pharmaceutical composition of claim 10, wherein the aqueous carrier material comprises GM-CSF.

21. The mRNA pharmaceutical composition of claim 10, wherein the human tumour-specific antigenic polypeptide is from a cancer selected from the group consisting of malignant melanoma, colon carcinoma, lymphoma, sarcoma, small-cell lung carcinoma, and blastoma.

22. The mRNA pharmaceutical composition according to claim 10, wherein the G/C content of the modified mRNA is increased at least by at least 15 percentage points relative to that of the wild type mRNA.

23. The mRNA pharmaceutical composition of claim 10 wherein the at least one modified mRNA encodes a human tumour-specific antigenic polypeptide selected from the group consisting of CEA, MUC1 and MAGE.

24. The mRNA pharmaceutical composition according to claim 1, wherein the G/C content of the modified mRNA is maximized.

25. The mRNA pharmaceutical composition according to claim 1, wherein the at least one modified mRNA is selected from the group consisting of mRNA encoding a PSA, PSM, MUC1, NY-ESO-1 and MAGE tumour antigen.

26. The mRNA pharmaceutical composition according to claim 25, wherein the at least one modified mRNA encodes a PSA tumour antigen.

27. The mRNA pharmaceutical composition according to claim 25, wherein the at least one modified mRNA encodes a PSM tumour antigen.

28. The mRNA pharmaceutical composition according to claim 25, wherein the at least one modified mRNA encodes a MUC1 tumour antigen.

29. The mRNA pharmaceutical composition according to claim 25, wherein the at least one modified mRNA encodes a NY-ESO-1 tumour antigen.

30. The mRNA pharmaceutical composition according to claim 25, wherein the at least one modified mRNA encodes a MAGE tumour antigen.

31. The mRNA pharmaceutical composition according to claim 1, wherein the at least one modified mRNA comprising at least one nucleotide position replaced with a nucleotide analogue selected from the group consisting of phosphorus amidates, phosphorus thioates, peptide nucleotides, methylphosphonates, 7-deazaguanosine, 5-methylcytosine and inosine.

32. A cell-free mRNA pharmaceutical composition comprising at least one modified mRNA and a pharmaceutically compatible carrier, wherein the modified mRNA encodes at least one human tumour-specific antigenic polypeptide capable of stimulating an immune response in a patient against the human tumour-specific antigenic polypeptide wherein said modified mRNA encoding the human tumour-specific antigenic polypeptide has been stabilized by increasing its Guanosine/Cytosine (G/C) content by at least 7 percentage points relative to that of the wild type mRNA encoding the tumour-specific antigenic polypeptide and wherein the tumour-specific antigenic polypeptide is selected from the group consisting of a PSA, PSM, MUC1, NY-ESO-1 and MAGE tumour antigen.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIG. 1 shows wild type sequences and modified sequences for the influenza matrix protein.

(2) FIG. 1A (SEQ ID NO: 1) shows the wild type gene and FIG. 1B (SEQ ID NO: 2) shows the amino acid sequence derived therefrom (1-letter code). FIG. 1C (SEQ ID NO: 3) shows a gene sequence coding for the influenza matrix protein, whose G/C content is increased as compared to that of the wild type sequence. FIG. 1D (SEQ ID NO: 4) shows the sequence of a gene that codes for a secreted form of the influenza matrix protein (including an N-terminal signal sequence), wherein the G/C content of the sequence is increased relative to that of the wild type sequence. FIG. 1E (SEQ ID NO: 5) shows an mRNA coding for the influenza matrix protein, wherein the mRNA comprises stabilising sequences not present in the corresponding wild type mRNA. FIG. 1F (SEQ ID NO: 6) shows an mRNA coding for the influenza matrix protein that in addition to stabilising sequences also contains an increased G/C content. FIG. 1G (SEQ ID NO: 7) likewise shows a modified mRNA that codes for a secreted form of the influenza matrix protein and comprises, as compared to the wild type, stabilising sequences and an elevated G/C content. In FIG. 1A and FIGS. 1C to 1G the start and stop codons are shown in bold type. Nucleotides that are changed relative to the wild type sequence of FIG. 1A are shown in capital letters in 1C to 1G.

(3) FIG. 2 shows wild type sequences and modified sequences according to the invention that encode for the tumour antigen MAGE1.

(4) FIG. 2A (SEQ ID NO: 8) shows the sequence of the wild type gene and FIG. 2B (SEQ ID NO: 9) shows the amino acid sequence derived therefrom (3-letter code). FIG. 2C (SEQ ID NO: 10) shows a modified mRNA coding for MAGE1, whose G/C content is increased as compared to the wild type. FIG. 2D (SEQ ID NO: 11) shows the sequence of a modified mRNA encoding MAGE1, in which the codon usage has been optimised as frequently as possible with respect to the tRNA present in the cell and to the coding sequence in question. Start and stop codons are shown in each case in bold type.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

(5) The following examples describe the invention in more detail and in no way are to be construed as restricting the scope thereof.

EXAMPLE 1

(6) As an exemplary embodiment of the process for determining the sequence of a modified mRNA according to the invention, a computer program was established that modifies the nucleotide sequence of an arbitrary mRNA in such a way as to maximise the G/C content of the nucleic acid, and maximise the presence of codons recognized by abundant tRNAs present in a particular cell(s). The computer program is based on an understanding of the genetic code and exploits the degenerative nature of the genetic code. By this means a modified mRNA having desirable properties is obtained, wherein the amino acid sequence encoded by the modified mRNA is identical to that of the unmodified mRNA sequence. Alternatively, the invention may encompass alterations in either the G/C content or codon usage of an mRNA to produce a modified mRNA.

(7) The source code in Visual Basic 6.0 (program development environment employed: Microsoft Visual Studio Enterprise 6.0 with Servicepack 3) is given in the Appendix I.

EXAMPLE 2

(8) An RNA construct with a sequence of the lac-Z gene from E. coli optimised with regard to stabilisation and translational efficiency was produced with the aid of the computer program of Example 1. A G/C content of 69% (compared to the wild type sequence of 51%; C. F. Kalnins et al., EMBO J. 1983, 2(4): 593-597) was achieved in this manner. Through the synthesis of overlapping oligonucleotides that comprise the modified sequence, the optimised sequence was produced according to methods known in the art. The terminal oligonucleotides have the following restriction cleavage sites: at the 5 end an EcoRV cleavage site, and at the 3 end a BglII cleavage site. The modified lacZ sequence was incorporated into the plasmid pT7Ts (GenBank Accession No. U26404; C. F. Lai et al., see above) by digestion with EcoRV/BglII. pT7Ts contains untranslated region sequences from the ?-globin gene of Xenopus laevis at the 5 and 3 ends. The plasmid was cleaved with the aforementioned restriction enzymes to facilitate insertion of the modified lacZ sequence having compatible 5 and 3 termini.

(9) The pT7Ts-lac-Z construct was propagated in bacteria and purified by phenol-chloroform extraction. 2 ?g of the construct were transcribed in vitro using methods known to a skilled artisan and the modified mRNA was produced.

EXAMPLE 3

(10) The gene for the influenza matrix protein (wild type sequence, see FIG. 1A; derived amino acid sequence, see FIG. 1B) was optimised with the aid of the computer program according to the invention of Example 1. The G/C-rich sequence variant shown in FIG. 1C (SEQ ID NO: 3) was thereby formed. A G/C-rich sequence coding for a secreted form of the influenza matrix protein, which includes an N-terminal signal sequence was also determined (see FIG. 1D; SEQ ID NO: 4). The secreted form of the influenza matrix protein has the advantage of increased immunogenicity as compared to that of the non-secreted form.

(11) Corresponding mRNA molecules were designed starting from the optimised sequences. The mRNA for the influenza matrix protein, optimised with regard to G/C content and codon usage, was additionally provided with stabilising sequences in the 5 region and 3 region (the stabilisation sequences derive from the 5-UTRs and 3-UTRs of the ?-globin-mRNA of Xenopus laevis; pT7Ts-Vektor in C. F. Lai et al., see above). See also FIG. 1E; SEQ ID NO: 5, which includes only stabilising sequences and IF; SEQ ID NO: 6, which includes both increased G/C content and stabilising sequences. The mRNA coding for the secreted form of the influenza matrix protein was likewise also sequence optimised in the translated region and provided with the aforementioned stabilising sequences (see FIG. 1G; SEQ ID NO: 7).

EXAMPLE 4

(12) The mRNA encoding the tumour antigen MAGE1 was modified with the aid of the computer program of Example 1. The sequence shown in FIG. 2C (SEQ ID NO: 10) was generated in this way, and has a 24% higher G/C content (351 G, 291 C) as compared to the wild type sequence (275 G, 244 G). In addition, by means of alternative codon usage, the wild type sequence was improved with regard to translational efficiency by substituting codons corresponding to tRNAs that are more abundant in a target cell (see FIG. 2D; SEQ ID NO: 11). The G/C content was likewise raised by 24% by the alternative codon usage.